Asia
Researchers at the Wuhan Institute of Virology (WIV), which is potentially linked to the origins of COVID-19, reported the discovery of a novel DNA virus in animals in the journal Virologica Sinica.
Clover’s SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines.
The United States and China are reportedly close to an agreement that would allow the PCAOB to audit companies listed on the U.S. stock exchange, per the Wall Street Journal.
AstraZeneca announced a series of wins in Japan with regulatory approvals for Tagrisso, Ultomiris and Lynparza, to treat non-small cell lung cancer, myasthenia gravis and breast cancer, respectively.
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.
The Bill & Melinda Gates Foundation inked a memorandum of understanding with South Korea’s foreign and health ministries to expand their partnerships revolving around public health.
Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
PRESS RELEASES